Takeda loses distribution of 13 Pfizer products in Japan
Japan’s largest drugmaker, Takeda Pharmaceutical (TYO: 4502), has concluded an agreement that, as of December 31, 2012, it will cease distribution of 13 out of the 15 products from global pharma behemoth Pfizer (NYSE: PFE) that it previously procured from Wyeth (which was acquired by Pfizer in 2009) and currently distributes under an exclusive distribution agreement with Pfizer.
But retains three
However, Takeda will continue to distribute the pneumococcus vaccine Prevenar for infants and young children and hemophilia B drug BeneFIX (nonacog alfa) after January 2013.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze